CARTARDIS
Identification and validation of novel pharmaceutical drug targets for cardiovascular disease
| Coordinatore | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO
Organization address
address: Schoemakerstraat 97 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Sito del progetto | http://cartardis.eu/ |
| Totale costo | 7˙980˙425 € |
| EC contributo | 5˙973˙521 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2017-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO
Organization address
address: Schoemakerstraat 97 contact info |
NL (DEN HAAG) | coordinator | 939˙353.00 |
| 2 |
CARDIOGENX BV
Organization address
address: LICHTENAUERLAAN 30 contact info |
NL (ROTTERDAM) | participant | 701˙024.00 |
| 3 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | participant | 700˙083.00 |
| 4 | POLYGENE AG | CH | participant | 697˙930.00 |
| 5 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 598˙000.00 |
| 6 |
HJARTAVERND SES
Organization address
address: HOLTASMARI 1 contact info |
IS (KOPAVOGUR) | participant | 499˙499.00 |
| 7 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 300˙720.00 |
| 8 |
BIONEER A/S
Organization address
address: KOGLE ALLE 2 contact info |
DK (HOERSHOLM) | participant | 296˙000.00 |
| 9 |
IMABIOTECH
Organization address
address: "CITE SCIENTIFIQUE BATIMENT SN 3, 1 ER ETAGE" contact info |
FR (VILLENEUVE D ASCQ) | participant | 296˙000.00 |
| 10 |
MORPHISTO EVOLUTIONSFORSCHUNG UND ANWENDUNG GMBH
Organization address
address: WEISMULLERSTRASSE 45 contact info |
DE (FRANKFURT AM MAIN) | participant | 295˙000.00 |
| 11 |
ASTRAZENECA AB
Organization address
address: Vastra Maelarhamnen contact info |
SE (SODERTAELJE) | participant | 250˙112.00 |
| 12 |
UMEA UNIVERSITET
Organization address
address: UNIVERSITETOMRADET contact info |
SE (UMEA) | participant | 200˙000.00 |
| 13 |
MAARTEN DANIEL SOLLEWIJN GELPKE
Organization address
address: SHERBROOKE WAY 64 contact info |
UK (WORCESTER PARK SURREY) | participant | 199˙800.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of ∼€ 192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The introduction of statins has reduced morbidity and mortality of atherosclerosis by 30%, however a large untreatable residual cardiovascularrisk remains even in cohorts of treated patients. Currently, many targets for CVD treatment have been selected based on mechanism of action and inference of functions in cellular models to clinical systems, and lack the rigorous clinical validation needed to maximize the chance for successful clinical drug development. Consequently, new drugs that modulate the activity of such targets fail later in clinical development by lack of efficacy or induction of safety liabilities due to off-target effects. To increase the success rate for clinical development of novel therapies in CVD, we will follow an innovative approach by using: 1. Independent and large-scale population studies from which novel targets with strong correlation to clinical phenotypes are deduced; 2. Translational disease-mimicking models (cellular and animal) to validate novel drug targets; 3. High quality human biobanks to confirm the molecular relevance of targets in diseased cardiovascular tissues; 4. A stringent pharmaceutical drug discovery process for prioritization of drugable targets. An important concept, in line with the changed pharmaceutical business model, is that these steps can best be executed by a functional network of clinical academic centers and specialized SMEs under the guidance of established and experienced drug discovery researchers from industry that brings together the right components and expertise to execute such a modular target discovery process.'